Large cell lymphomas (LCLs) are heterogeneous in morphology, clinical presentation, and behavior. We studied 52 de novo LCLs of B-cell type for rearrangements of the bcl-2 and c-myc oncogenes by Southern blot analysis and related these data to the primary site of presentation, stage, and cytomorphology. Thirteen tumors had comigrating rearrangements of JH and bcl-2, indicative of a t(14;18). Far more primary nodal lymphomas than extranodal lymphomas carried a t(14;18) (40% Y < 5%). Additionally, almost all lymphomas with a t(14;18) versus 41% of the tumors without a bcl-2 PECIFIC CHROMOSOMAL translocations are associ-S ated with distinct types of non-Hodgkin's lymphomas (NHL). These translocations include t(8;14) and its variants t(2;8) and t(8;22) in Burkitt's lymphoma,',* t(14;18) in follicular lymphoma, 334 and t( 11;14) in centrocytic lymp h~m a ,~.~ involving the c-myc, bcl-2, and bcl-1 loci, respectively. By karyotyping, a t(14;18) has been identified in up to 85% to 90% of all cases of follicular l y m p h~m a '~~~*~~ and most translocations can be detected by Southern blot analy~is.~.'"." The reported incidence of t( 14;18) translocations in diffuse large cell lymphoma (LCL) of B-cell origin is lower and ranges from 12% to 40%.4.'2.12
rearrangement presented with lymphadenopathy. c-myc rearrangements were seen in 35% of the extranodal lymphomas and 5% of the nodal lymphomas. No differences were observed in bone marrow involvement and staging according to Ann Arbor. bcl-2 rearrangements were found in 50% of the LCLs with cleaved nuclei, whereas c-myc rearrangements were relatively frequent (25%) in the noneleaved subtype. Our data support the hypothesis that primary nodal and extranodal lymphomas have a different genetic origin.
o 1991 by The American Society of Hematology.
cially GI-lymphomas. These data indicate essential differences in tumorigenesis and might also explain the differences in the literature on the incidence of t(14;18) in LCLs.
PATIENTS AND METHODS
Patients and histology. Fifty-two cases of B-cell LCLs were collected from the frozen tissue bank of the Laboratory of Pathology, University of Leiden. The series includes 46 cases derived from a registration of NHL in the region of the Comprehensive Cancer Center West (CCCW). It comprises all de novo centroblastic lymphomas investigated by Southern blot analysis in our laboratory and includes 24 cases published All cases were diagnosed between 1981 and 1990 and were revised accordingly to the updated Kiel classification.*' Four histologic types were distinguished: centroblastic lymphomas of the monomorphic, polymorphic, multilobated, and the centrocytoid subtype; we additionally discerned a fifth subgroup with a predominance of centroblasts, but admixed with (small) centrocytes. Cases with a histologically documented pre-existent phase of follicular lymphoma, and immunoblastic lymphomas were excluded. All tumors had been identified as B-cell lymphomas by immunohistochemistry on frozen tissue sections. This identification included analysis with CD19, CD20, and CD22 monoclonal antibodies (MoAbs) and with polyclonal antibodies for detection of Igs." ' The clinical data were reviewed for all patients, focusing on the primary sites of involvement and staging (Table 1) . The staging procedure consisted of a physical examination, a chest X-ray, a CT-scan of the abdomen, bone marrow (BM) examination by cytology and histology of a Jamshidi needle biopsy, liver function tests, and an ENT-consultation. The lymphomas were classified as primary nodal or extranodal according to the (pathologically documented) site(s) of clinical pre~entation'~.** (see Table 1 ).
In all patients only the original (either nodal or extranodal) tumor specimen was investigated. High molecular weight DNA was isolated from frozen tumor biopsies using standard methods. The DNAs were digested to completion with various restriction enzymes, size fractionated in 0.7% agarose gels, and transferred to Genescreen Plus (Dupont NEN Products, Boston, MA) or Amersham Hybond-N (Amersham, UK) filters. Blots were hybridized with random primer "P-labeled probes, washed in 0.3X SSC/O.l% sodium dodecyl sulfate (SDS) at 65°C and autoradiographed at -70°C. The filters were reused with different probes after removal of the previous signal by washing in 0.1X SSCJO.1% SDS at 100°C. EcoRI, BamHI, and Hind111 digestions were performed in all cases. Ig heavy chain (IgH) gene rearrangements were detected with a 2. 4 
Pleura, lung For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Ig K genes were studied with a 1.8-kb SucI-Sac1 JK probe in EcoRIand HindIII-digested DNA and A gene rearrangements with a 3.5-kb EcoRI-Hind111 Ch probe, using EcoRI-digested DNA (the Ig probes were kindly provided by P. Leder, Boston, MA). Rearrangements of the bcl-2 gene were studied by hybridizing the filters with a 2.8-kb EcoRI-Hind111 fragment of the bcl-2 gene containing the major breakpoint area (mbr)*' (kindly provided by Y . Tsujimoto, Philadelphia, PA) and a 4.0-kb EcoRI-Hind111 fragment containing the minor cluster region (mcr; pF1-2)" (kindly provided by M.L. Cleary, Stanford, CA). The c-myc gene was studied with a 2.0-kb EcoRI-EcoRI cDNA probe (kindly provided by T. Rabbitts, MRC, Cambridge, UK). Table 1 shows the clinical data of the 52 patients, including clinically and/or pathologically documented tumor sites, and the staging data according to the Ann Arbor classification. In 20 patients, the lymphoma presented with lymphadenopathy, and these were classified as primary nodal. Staging showed additional extranodal tumor sites in five of these patients. In 5 of 17 patients with an adequate BM biopsy, the marrow contained tumor. According to the Ann Arbor system 2 of the 17 adequately staged patients had stage I disease. Four additional patients presented with a tonsillar localization. Three of these four also presented with cervical lymphadenopathy and one patient had a positive BM on staging.
RESULTS
Twenty-three patients presented with extranodal disease: stomach (N = lo), intestine (N = 3), testis (N = 2), (para)nasal (N = 2), pleura (N = l), bone (N = l), and soft tissues (N = 4). The subsequent staging showed that three patients had multiple extranodal tumor sites, ie, liver in two cases, lung/pleura in one patient, and additional lymph node involvement in 10 cases. In 2 of 19 evaluable patients the BM contained tumor. Eleven of the 21 adequately staged patients had stage I disease. Five patients presented with both extensive nodal and extranodal disease (thyroid, stomach, lung, pleura, liver, bone, soft tissues, dura, and liquor). In four of these patients, the BM was also positive.
All tumors had clonal rearrangements of the JH gene in at least two different digests, indicating the presence of a clonal B-cell population in the material analyzed. Tables 1  and 2 show the incidence of bcl-2 and c-myc rearrangements in the different lymphomas. Eight of the 20 primary nodal lymphomas and two of the four primary tonsillar lymphomas showed a rearrangement of bcl-2. These two lymphomas of the tonsil also presented with cervical lymphadenopathy. Only 1 of the 23 primary extranodal cases had a rearrangement of bcl-2. This tumor presented in and around the scapula. bcl-2 rearrangements were also found in two of five cases presenting with extensively disseminated nodal and extranodal lymphoma. Notably, 12 of 13 lymphomas (92%) with a bcl-2 rearrangement presented with lymphadenopathy, versus 16 of 39 lymphomas (41%) without such a rearrangement.
Oncogene rearrangements were also studied in relation to the staging data. The association of bcl-2 rearrangement with nodal involvement persisted: in all 13 patients with a bcl-2 rearrangement, lymph nodes were involved. In con- tEleven of 12 cases with a rearrangement were detected with the mbr probe, one case with the mcr (pFL-2) probe. In four cases (one nodal, three extranodal) a rearrangement within the mcr was not investigated because of a lack of material. One of these four cases had a c-myc rearrangement, making it unlikely that this IgH-positive tumor had an additional t(14;18).
Significant difference (x'test with Yates correction; P < .05).
trast, lymph node involvement was absent in 33% (13 of 39) of the tumors without a bcl-2 rearrangement. We could not find any correlation between oncogene rearrangement and BM involvement or staging according to the Ann Arbor system.
In all cases with a bcl-2 rearrangement, comigration with a rearranged IgH gene sequence was detected with the JH probe, indicating a t( 14;18). The bcl-2 rearrangements involved the mbr in 12 tumors, and the mcr in one case.
c-myc rearrangements were predominantly found in primary extranodal LCLs (8 of 23 cases), in particular in GI lymphomas (6 of 13 cases); the two other sites were pleura and skeletal muscle. One nodal lymphoma showed a c-myc rearrangement. No correlation between c-myc rearrangement and BM involvement or stage was found. Comigration of rearranged c-myc and JH gene sequences was present in two of nine cases. No comigration with C-K or c-A light chain genes was found. Table 2 shows the frequency of oncogene rearrangements for the different cytomorphologic subtypes of LCL according to the Kiel classification. bcl-2 rearrangements were relatively frequent (50%) in multilobated and centrocytoid subtypes of centroblastic lymphoma, which can be For personal use only. on October 3, 2017. by guest www.bloodjournal.org From compared with the large cleaved lymphoma in the working formulation (WF). They were also found in three of nine centroblastic lymphoma with a relative high content of centrocytes. This association with morphology was especially prominent in the primary nodal cases: 8 of 12 cases with this morphology versus 2 of 12 with a mono/ polymorphic morphology contained a t( 14;18). In contrast, c-myc rearrangements were more frequent in the mono/ polymorphic subtypes of centroblastic lymphoma, representing the large noncleaved lymphoma in the WF (7 of 29 cases, in contrast to 2 of 23 cases with other morphologies).
DISCUSSION
Important differences in oncogene rearrangements exist between primary nodal and extranodal LCLs of B-cell origin. Using Southern blot analysis, we showed that the t(14;18) was far more frequent in primary nodal than in extranodal lymphoma. This association with involvement of lymph nodes persisted if the staging was taken into account. Vice versa, rearrangements of c-myc were far more frequent in extranodal lymphomas, especially in the GI tract. These data give more general significance to separate reports on the absence of bcl-2 rearrangements in GI and primary cutaneous lymphomas of B-cell origin17 and the presence of c-myc rearrangements in GI lymphomas.'6 In addition to tumor site, a relationship between cellular morphology and oncogene rearrangements emerged from the present study, especially in the nodal cases. We cannot exclude, however, that these correlations between oncogene involvement, tumor site, and morphology are interdependent.
The frequency of bcl-2 rearrangements in de novo nodal LCL (40%) is approximately equal to that observed in follicular lymphoma by Southern blot analysis, which ranges from 30% to 69%.L0~"s25 Possibly, we have introduced a positive selection of t( 14;18) carrying lymphomas, because we included seven IgH-negative lymphomas, five of which carried a t( 14;18), as published before.20 In that study, we showed that the presence of a chromosomal breakpoint within the IgH locus at 14q32.3 contributes to a defect in IgH expression,m which is observed in about 30% of the centroblastic lymphomas. On the other hand, bcl-2 rearrangements may have been missed, because three cases without a bcl-2 or c-myc rearrangement could not be analyzed with the pFL-2 probe. However, these possible inaccuracies do not interfere with our conclusions concerning the association of oncogene involvement with tumor site and morphology.
The differences in incidence of t(14;18) between nodal and extranodal lymphomas might explain the wide range of 12% to 40% reported for this rearrangement in LCLs."'0~121325 We and others have shown that extranodal lymphomas comprise about 40% of all NHL and that LCLs are especially frequent at extranodal sites.I4 Thus, the frequency of the t(14;18) may largely depend on the relative contribution of nodal and extranodal lymphomas in particular studies. Only in the study of Lee et al'" were data on tumor sites given. They showed that 8 of 20 cases with de novo LCL had a rearrangement of bcl-2. Seemingly in contrast to our results, bcl-2 rearrangements were particularly frequent in lymphomas with extranodal involvement. However, no data were given on the primary presentation of these tumors and most tissue samples used for Southern blotting had been derived from lymph nodes. Beyond doubt, it is necessary to confirm the present results in a prospective analysis of a large and unselected series of patients with LCL.
Our data hint at a fundamentally different genesis of LCLs with or without bcl-2 and c-myc rearrangements. In follicular lymphoma, the t( 1q18) and, in consequence, activation of the bcl-2 oncogene, probably is a primary oncogenic event taking place in (BM) precursor B cells.26-28 The resulting cells subsequently home to lymph nodes, where the follicular lymphoma will grow out. Yunis et a1 and others have shown that chromosomal abnormalities additional to the t(14;18) are associated with tumor progresThese additional abnormalities may sion to LCL.I3,' 8.29-32 occur very early during tumorigenesis, and before clinical pre~entation.~'*~~ Such an early evolution is further supported by the observation that some patients with de novo LCL have a recurrence of follicular lymphoma after therapY34-36 and that many patients with de novo LCL have a low grade component within the BM.37-39 Interestingly, the latter tumors seem to behave like follicular lymphoma as they are characterized by frequently relapsing disease." A similar origin from early tumor progression has been proposed for the sporadic t(14;18) containing acute lymphoblastic leukem i a~. " .~ To some extent this sequence of events may be compared with the presentation of chronic granulocytic leukemia by an early blast crisis of a t(9;22)-positive acute leukemia.
In contrast, extranodal LCLs seem to have a different origin in the extranodal tissue itself. This finding is strongly supported by the fact that almost half of the tumors are localized (stage IE; Table 1 ) and can be cured by surgery andlor radiotherapy. As already reported earlier by our group, half of the primary GI LCLs have a c-myc rearrangement. In most cases with this rearrangement we could not identify any comigrating Ig gene sequence (tested with probes for JH, IgH switch regions, and C-K and c-A genes) that might hint at a chromosomal translocation t(8;14), t(2;8), or t(8;22) as observed in Burkitt's lymphoma. Apparently, the rearrangement of c-myc in these GI lymphomas has a different origin. We proposed that the c-myc rearrangement in gastric lymphoma may be related to tumor progression from a low grade lymphoma arising in the mucosaassociated lymphoid tissue, rather than to primary lymphomagenesis.16 In conclusion, our results show that oncogene analysis may be of help in understanding the biology and the heterogeneous presentation and behavior of diffuse LCLs. 
